JonathanWadeGoldmanMD

Oncology • Santa Monica, CA

Physician

Join to view full profile

Dr. Goldman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldman's full profile

Already have an account?

Office
2020 Santa Monica Blvd
Ste 600
Santa Monica, CA 90404
Phone+1 310-633-8400

Fax+1 310-633-8419

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2003 - 2025

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Completed
Phase 1, Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Jan 29
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC Start of enrollment: 2022 Oct 10
Recruiting
Phase 1
Roles: Contact
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Start of enrollment: 2023 Sep 13
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping...
Matthew S Lara, Jonathan W Riess, Jonathan W Goldman, Fei Jiang, Trever G Bivona
Clinical Lung Cancer. 2024-12-01
Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancer.
Anitha Chandrasekhar, Hee Chul Yang, Tarik Demir, Anjana Yeldandi, Chitaru Kurihara
American Journal of Transplantation. 2024-09-13
5 citations
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous-Wildtype Non-Small Cell Lung Cancer in the Phas...
D Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan Goldman, Fedor Moiseenko
Journal of Clinical Oncology. 2024-09-01

Lectures

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

High-Dose Radiotherapy with Chemotherapy Effective in Treating People with Non-Small Cell Lung CancerJanuary 11th, 2024
Many Patients with NSCLC Receive Immunotherapy ‘Indefinitely’ – Are They Benefiting?September 18th, 2023
CASPIAN Trial Update: Phase 3 Results & PerspectivesJune 23rd, 2020
Join now to see all

JonathanWadeGoldmanMD

Dr. Goldman is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.